The platform's decentralized AI agents autonomously generate hypotheses, manage funding, learn from encrypted data, and create blockchain-verified knowledge flows, revolutionizing biotech research.

Funding will also be used to scale the platform's launchpad, develop features like prediction markets and onchain lending, and support the global growth of the decentralized biotech ecosystem.

Since 2024, Bio Protocol has directed over $50 million in research funding to projects like VITA-FAST, Percepta, and Curetopia, which are progressing toward clinical milestones at reduced costs and timelines.

The first BioAgent, Aubrai, launched in August 2025, has already generated over $900,000 in research funding, minted more than 1,000 hypotheses, and enables immediate lab testing through automated workflows.

Aubrai, developed with VitaDAO and Dr. Aubrey de Grey, has raised $250,000, minted over 1,000 hypotheses onchain, and its token surged 150x from pre-sale valuation to a peak of about $40 million.

The recent funding coincides with the launch of Bio V2, an upgraded platform offering advanced onchain funding, governance, and incentive structures like Ignition Sales, BioXP loyalty, and staking mechanisms.

Bio V2 introduces new tools such as prediction markets, onchain lending, and enhanced governance features to support the growth of BioAgents and the decentralized biotech ecosystem.

Bio V2 aims to expand its network of BioAgents across diverse fields like dermatology, microbiome health, and brain health, with plans to launch more agents and intellectual property tokens.

Funding will support the creation of onchain AI agents called BioAgents, which are designed to reduce research costs and speed up scientific breakthroughs.

Bio Protocol aims to democratize biotech innovation, making research more accessible and accelerating drug development worldwide by breaking down traditional barriers.

Industry observers see Bio Protocol as a transformative force in biotech, with potential to significantly shorten drug development timelines through decentralized AI-driven science.

Bio Protocol has secured $6.9 million in funding, led by Maelstrom Fund, to develop a decentralized, AI-native platform for biotech research, funding, and drug discovery, aiming to accelerate scientific progress.

The platform integrates scientific AI with blockchain technology to enhance coordination, data integrity, and funding, facilitating a faster transition from hypotheses to commercial applications.